PFE Cash & equivalents
Cash & equivalents at Pfizer rose to $1.1B in fiscal 2025, from $1.0B in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 78003 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$1.1B
FY2024 $1.0B
HIGH$2.9B FY2023
LOW$416M FY2022
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $1.1B | +$99M |
| FY2024 | $1.0B | $-1.8B |
| FY2023 | $2.9B | +$2.4B |
| FY2022 | $416M | $-1.5B |
| FY2021 | $1.9B | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · PFE company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.